个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Chen Bolin[1] ; Yao Wenxiu[2] ; Li Xingya[3] ; Lin Gen[4] ; Chu Qian[5] ; Liu Hailong[6] ; Du Yingying[7] ; Lin Jie[8] ; Duan Huaxin[9] ; Wang Huijuan[10] ; Xiao Zemin[11] ; Sun Hong[12] ; Liu Liyu[1] ; Xu Li[1] ; Xu Yan[1] ; Xu Fang[1] ; Kong Yi[1] ; Pu Xingxiang[1] ; Li Kang[1] ; Wang Qianzhi[1] ; Li Jia[1] ; Li Baiyong[13] ; Xia Yu[13] ; Wu Lin[1] ;
机构： [1]The Second Department of Thoracic Medicine, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. [2]Department of Oncology, Sichuan Cancer Hospital, Chengdu, China. [3]The Second Ward, Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. [4]Department of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, China. [5]Department of Thoracic Oncology, Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, China. [6]Department of Oncology, Chenzhou First People's Hospital, Chenzhou, China. [7]Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. [8]Department of Medical Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. [9]Department of Oncology, Hunan Provincial People's Hospital /The First Affiliated Hospital of Hunan Normal University, Changsha, China. [10]The Second Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, China. [11]Department of Oncology, The First People's Hospital of Changde City, Changde, China. [12]Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [13]Akeso Biopharma, Inc, Zhongshan, China.
出处：
DOI： 10.1038/s41416-023-02519-0
ISSN：

摘要：
Cadonilimab is a bispecific antibody that simultaneously targets programmed cell death receptor-1 and cytotoxic T lymphocyte-associated antigen-4. This study aimed to assess the safety and efficacy of cadonilimab plus anlotinib for the first-line treatment of advanced non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK/ROS1 mutations.Patients received cadonilimab 15 mg/kg and 10 mg/kg every three weeks (Q3W) plus anlotinib at doses of 10 or 12 mg once daily for two weeks on a one-week-off schedule. The primary endpoints included safety and objective response rate (ORR).Sixty-nine treatment-naïve patients received cadonilimab 15 mg/kg Q3W combination (n = 49) and 10 mg/kg Q3W combination (n = 20). Treatment-related adverse events (TRAEs) were reported in 48 (98.0%) and 19 (95.0%) patients, with grade ≥3 TRAEs occurring in 29 (59.2%) and five (25.0%) patients, respectively. TRAEs leading to cadonilimab discontinuation occurred in eight (16.3%) and one (5.0%) patients in the cadonilimab 15 mg/kg Q3W and 10 mg/kg Q3W dosing groups. The confirmed ORRs were 51.0% (25/49) and 60.0% (12/20) accordingly.Cadonilimab 10 mg/kg Q3W plus anlotinib showed manageable safety and promising efficacy as a first-line chemo-free treatment for advanced NSCLC.NCT04646330.© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

基金：
Akeso Biopharma, Inc. and The Science and Technology Innovation Program of Hunan Province (2023SK4024).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]The Second Department of Thoracic Medicine, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Chen Bolin,Yao Wenxiu,Li Xingya,et al.A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer[J].BRITISH JOURNAL OF CANCER.2024,130(3):450-456.doi:10.1038/s41416-023-02519-0.
APA：
Chen Bolin,Yao Wenxiu,Li Xingya,Lin Gen,Chu Qian...&Wu Lin.(2024).A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.BRITISH JOURNAL OF CANCER,130,(3)
MLA：
Chen Bolin,et al."A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer".BRITISH JOURNAL OF CANCER 130..3(2024):450-456

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号